GENEREX BIOTECHNOL COM USD 0.001 (GNBT)

4.00
0.00 (0.00)
OTC
Prev Close 4.00
Open 4.00
Day Low/High 4.00 / 4.00
52 Wk Low/High 2.00 / 20.00
Volume 100.00
Exchange OTC
Shares Outstanding 1.07B
Market Cap 4.27M
Div & Yield N.A. (N.A)

Latest News

Generex Announces Reverse Stock Split

Generex Biotechnology Corporation (OTCPink:GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000.

Generex Provides Access Information For Investor Conference Call Scheduled For February 22, 2017

Generex Biotechnology Corporation (OTCPink:GNBT) today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his...

Generex Announces Elimination Of Outstanding Derivative Securities

Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it has achieved the elimination of its outstanding derivative securities.

Generex Provides Update On Deal To Acquire Controlling Equity Interest In Emmaus Life Sciences, Inc.

On January 23, 2017 Generex Biotechnology Corporation (OTCPink:GNBT) announced a letter of intent for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc.

Generex Announces Investor Conference Call

Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it will hold an investor conference call at 10 a.

Generex Welcomes Dr. Yutaka Niihara, M.D., M.P.H. To Its Board Of Directors

Generex Welcomes Dr. Yutaka Niihara, M.D., M.P.H. To Its Board Of Directors

Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that Dr.

Generex Announces Deal To Acquire Controlling Equity Interest In Emmaus Life Sciences, Inc.

Generex Announces Deal To Acquire Controlling Equity Interest In Emmaus Life Sciences, Inc.

Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 16, 2017 it entered into a letter of intent (the " LOI") for the acquisition of a controlling equity interest in Emmaus Life Sciences,...

Generex Announces Closing Of Acquisition Of Controlling Equity Interest In Hema Diagnostic Systems

Generex Announces Closing Of Acquisition Of Controlling Equity Interest In Hema Diagnostic Systems

Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 19, 2017 it consummated the previously announced acquisition of a controlling equity interest in Hema Diagnostic Systems, LLC ( www.

Biotech Stock Mailbag: Generex

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Generex Oncology Announces Consultancy Of Dr. George E. Peoples, MD

Cancer Vaccine Specialist to Assist in the On-Going Clinical and Regulatory Development of the Company's Proprietary Breast Cancer Vaccine

Generex Biotechnology Initiates Social Media Campaign For Its Corporate And E-Commerce Websites

Online Efforts Will Focus on Glucose RapidSpray(TM), Crave-NX(TM) Diet Spray, BaBoom!(TM) Energy Spray and Glucose RapidSpray(TM) for Pets(TM)

Generex Biotechnology Creates Scientific Advisory Board To Further The Progression Of Its Drug Development Programs

Anticipates Adding Several Industry Leaders in the Fields of Oncology and Metabolic Science in the Coming Weeks

Generex Announces AGM Results

Generex Provides Positive Update On Generex Oral-Lyn(TM) Pivotal Phase III Trial

Study Has Now Achieved 75% of the Required Number of Per-Protocol Completers

Generex Biotechnology To Participate In World's Largest And Most Prestigious Diabetes Meeting

Company to Exhibit Its Full Spectrum of Proprietary Diabetes Products During the 70th American Diabetes Association Scientific Sessions

Biotech Stock Mailbag: Spectrum Pharma

Biotech watchdog Adam Feuerstein answers readers' questions about drug and health care companies.

Generex Biotechnology Reports Preliminary Outcomes And Trends From Ongoing Phase III Clinical Trial Of Generex Oral-lyn(TM)

Findings Based on In-Process Data for Subjects That Completed the 6-Month Treatment Phase of the Study Demonstrate Several Favorable Comparisons to Injectable Insulin

Generex Awarded Two New Patents For Its Proprietary Buccal Drug Delivery System

New Patents Also Cover Method of Preparation as Well as Method of Administration